The Latest Data Specifically Focused on Long-Term Oncologic Prognostication for Very Old Adults with Acute Vulnerable Localized Prostate Cancer: A Nationwide Cohort Study

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Jun 24

PMID 35743522

Authors

Szu-Yuan Wu

Fransisca Fortunata Effendi

Ricardo E Canales

Chung-Chien Huang

Affiliations

Soon will be listed here.

Abstract

Purpose: Few studies have evaluated the prime treatment choice for men older than 80 years with acute vulnerable localized prostate cancer (AV-LPC). Clinicians have been deeply troubled by this near end-of-life medical choice for a very specific group of patients. We compared the oncological prognostication of very old patients with AV-LPC after they underwent either radical prostatectomy (RP) or massive-dose intensity-modulated radiotherapy (IMRT) coupled with long-term androgen deprivation therapy (ADT) over a long-term investigation. Methods: In this nationwide cohort study, we used the Taiwan Cancer Registry Database and retrieved information related to patients (aged ≥ 80 years) with AV-LPC who underwent standard RP (the RP group) or massive-dose IMRT + long-term ADT (at least 72 Gy and ADT use ≥18 months; the IMRT + ADT group). After potential confounders were controlled for using propensity score matching (PSM), we utilized the Cox proportional hazards regression to evaluate the oncologic prognostication. Results: The IMRT + ADT group had a significantly higher adjusted hazard ratio (aHR) for all-cause mortality (aHR, 2.00; 95% confidence interval [CI], 1.41−2.87) than the RP group. Analysis of the secondary outcomes revealed that compared with the RP group, the aHRs of biochemical failure, locoregional recurrence, and distant metastasis in the IMRT + ADT group were 1.77 (95% CI: 1.36−2.11, p < 0.0001), 1.12 (95% CI: 1.04−1.33, p < 0.0001), and 1.15 (95% CI: 1.06−1.71, p = 0.0311), respectively. Conclusion: RP provides more favorable oncological prognostication than IMRT in very old adults with AV-LPC.

Citing Articles

Six-year outcomes of robot-assisted radical prostatectomy versus volumetric modulated arc therapy for localized prostate cancer: A propensity score-matched analysis.

Noda M, Taguchi S, Shiraishi K, Fujimura T, Naito A, Kawai T Strahlenther Onkol. 2024; 200(8):676-683.

PMID: 38180494 PMC: 11272719. DOI: 10.1007/s00066-023-02192-5.

Efficacy and Complications of the Re-Adjustable Male Sling System for Stress Urinary Incontinence after Radical Prostatectomy.

Chiu L, Chen W, Hsieh P, Chen Y, Huang C J Clin Med. 2022; 11(22).

PMID: 36431241 PMC: 9698314. DOI: 10.3390/jcm11226764.

References

Austin P . Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2010; 10(2):150-61. PMC: 3120982. DOI: 10.1002/pst.433. View

Zhang J, Lu C, Chen H, Wu S . Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity. JAMA Netw Open. 2021; 4(3):e211785. PMC: 7955271. DOI: 10.1001/jamanetworkopen.2021.1785. View

Wu S, Fang S, Shih H, Wen Y, Shao Y . Mortality associated with statins in men with advanced prostate cancer treated with androgen deprivation therapy. Eur J Cancer. 2019; 112:109-117. DOI: 10.1016/j.ejca.2018.11.032. View

Ling D, Kabolizadeh P, Heron D, Ohr J, Wang H, Johnson J . Incidence of hospitalization in patients with head and neck cancer treated with intensity-modulated radiation therapy. Head Neck. 2014; 37(12):1750-5. DOI: 10.1002/hed.23821. View

Cooperberg M, Cowan J, Broering J, Carroll P . High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008; 26(3):211-8. PMC: 2948572. DOI: 10.1007/s00345-008-0250-7. View

Sun L, Caire A, Robertson C, George D, Polascik T, Maloney K . Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol. 2009; 182(5):2242-8. DOI: 10.1016/j.juro.2009.07.034. View

Liao H, Duan X, Du Y, Mou X, Hu T, Cai T . Radical prostatectomy after previous transurethral resection of the prostate: oncological, surgical and functional outcomes-a meta-analysis. World J Urol. 2019; 38(8):1919-1932. DOI: 10.1007/s00345-019-02986-2. View

Wu S, Chang S, Chen C, Huang C . Oncologic Outcomes of Radical Prostatectomy and High-Dose Intensity-Modulated Radiotherapy with Androgen-Deprivation Therapy for Relatively Young Patients with Unfavorable Intermediate-Risk Prostate Adenocarcinoma. Cancers (Basel). 2021; 13(7). PMC: 8036838. DOI: 10.3390/cancers13071517. View

Kensler K, Pernar C, Mahal B, Nguyen P, Trinh Q, Kibel A . Racial and Ethnic Variation in PSA Testing and Prostate Cancer Incidence Following the 2012 USPSTF Recommendation. J Natl Cancer Inst. 2020; 113(6):719-726. PMC: 8168268. DOI: 10.1093/jnci/djaa171. View

10.

Zereshkian A, Cao X, Puts M, Dawdy K, Prospero L, Alibhai S . Do Canadian Radiation Oncologists Consider Geriatric Assessment in the Decision-Making Process for Treatment of Patients 80 years and Older with Non-Metastatic Prostate Cancer? - National Survey. J Geriatr Oncol. 2019; 10(4):659-665. DOI: 10.1016/j.jgo.2019.01.015. View

11.

Ko Y, Park S, Ha U, Joung J, Jeong S, Byun S . A comparison of the survival outcomes of robotic-assisted radical prostatectomy and radiation therapy in patients over 75 years old with non-metastatic prostate cancer: A Korean multicenter study. Investig Clin Urol. 2021; 62(5):535-544. PMC: 8421997. DOI: 10.4111/icu.20210079. View

12.

Rice K, Colombo M, Wingate J, Chen Y, Cullen J, McLeod D . Low risk prostate cancer in men ≥ 70 years old: to treat or not to treat. Urol Oncol. 2011; 31(6):755-60. DOI: 10.1016/j.urolonc.2011.07.004. View

13.

Zhang J, Lu C, Qin L, Chen H, Wu S . Breast-conserving surgery with or without irradiation in women with invasive ductal carcinoma of the breast receiving preoperative systemic therapy: A cohort study. Breast. 2020; 54:139-147. PMC: 7559874. DOI: 10.1016/j.breast.2020.09.010. View

14.

Zhang J, Lu C, Chen C, Chen H, Wu S . Effect of pathologic stages on postmastectomy radiation therapy in breast cancer receiving neoadjuvant chemotherapy and total mastectomy: A Cancer Database Analysis. Breast. 2020; 54:70-78. PMC: 7501458. DOI: 10.1016/j.breast.2020.08.017. View

15.

Hao S, Ostensson E, Eklund M, Gronberg H, Nordstrom T, Heintz E . The economic burden of prostate cancer - a Swedish prevalence-based register study. BMC Health Serv Res. 2020; 20(1):448. PMC: 7238534. DOI: 10.1186/s12913-020-05265-8. View

16.

Rawla P . Epidemiology of Prostate Cancer. World J Oncol. 2019; 10(2):63-89. PMC: 6497009. DOI: 10.14740/wjon1191. View

17.

Bill-Axelson A, Holmberg L, Garmo H, Rider J, Taari K, Busch C . Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014; 370(10):932-42. PMC: 4118145. DOI: 10.1056/NEJMoa1311593. View

18.

Vernooij R, van Oort I, de Reijke T, Aben K . Nationwide treatment patterns and survival of older patients with prostate cancer. J Geriatr Oncol. 2019; 10(2):252-258. DOI: 10.1016/j.jgo.2018.06.010. View

19.

Wu S, Chang S, Chen C, Huang C . Latest Comprehensive Medical Resource Consumption in Robot-Assisted versus Laparoscopic and Traditional Open Radical Prostatectomy: A Nationwide Population-Based Cohort Study. Cancers (Basel). 2021; 13(7). PMC: 8037789. DOI: 10.3390/cancers13071564. View

20.

Cooperberg M, Vickers A, Broering J, Carroll P . Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010; 116(22):5226-34. PMC: 2975879. DOI: 10.1002/cncr.25456. View